Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867015745977712640 |
|---|---|
| author | Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita |
| author_facet | Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita |
| collection | Wiley Open Access |
| contents | Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita BJUI Compass AbstractRenal cell carcinoma (RCC) affects 10%–20% of patients annually, often with metastases present. This study evaluated the impact of systemic therapy before nephrectomy in patients with unresectable or metastatic renal cell carcinoma (RCC). Patients receiving upfront immune checkpoint inhibitor (ICI) combination therapy showed significantly improved progression‐free survival (PFS) compared to nephrectomy alone (2‐year PFS: 62.3% vs. 17.4%; p = 0.036), while upfront tyrosine kinase inhibitor (TKI) therapy did not (2‐year PFS: 18.2% vs. 12.3%; p = 0.545). Surgery‐related outcomes did not differ significantly between groups. ICI therapy maintained tumour reduction rates better than TKI therapy. The study highlights the potential benefits of ICI combination therapy over TKI therapy in advanced RCC, suggesting further research is needed to confirm these findings. 10.1002/bco2.419 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/bco2.419 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_bco2_419 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita BJUI Compass Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study Sho Kiyota Takashi Yoshida Takahiro Nakamoto Eri Jino Takao Mishima Hidefumi Kinoshita BJUI Compass AbstractRenal cell carcinoma (RCC) affects 10%–20% of patients annually, often with metastases present. This study evaluated the impact of systemic therapy before nephrectomy in patients with unresectable or metastatic renal cell carcinoma (RCC). Patients receiving upfront immune checkpoint inhibitor (ICI) combination therapy showed significantly improved progression‐free survival (PFS) compared to nephrectomy alone (2‐year PFS: 62.3% vs. 17.4%; p = 0.036), while upfront tyrosine kinase inhibitor (TKI) therapy did not (2‐year PFS: 18.2% vs. 12.3%; p = 0.545). Surgery‐related outcomes did not differ significantly between groups. ICI therapy maintained tumour reduction rates better than TKI therapy. The study highlights the potential benefits of ICI combination therapy over TKI therapy in advanced RCC, suggesting further research is needed to confirm these findings. 10.1002/bco2.419 http://creativecommons.org/licenses/by/4.0/ |
| title | Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study |
| topic | BJUI Compass |
| url | https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.419 |